New insider activity at Crispr Therapeutics AG ( (CRSP) ) has taken place on August 8, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Director Douglas A Treco has made a significant investment in Crispr Therapeutics AG by purchasing 20,000 shares of the company’s stock. This transaction is valued at $1,140,600, indicating a strong vote of confidence in the company’s future prospects.
Recent Updates on CRSP stock
Crispr Therapeutics AG has recently announced updates on its ongoing clinical study for CTX112, a CRISPR-Cas9-engineered T cell therapy targeting refractory autoimmune diseases. This development is significant as it explores innovative gene-editing technology, potentially transforming treatment options for challenging conditions like systemic lupus erythematosus. Additionally, the company’s Q2 earnings report highlighted progress in clinical and commercial programs, including the activation of 75 authorized treatment centers for CASGEVY® therapy. Despite reporting a net loss due to new R&D collaborations, Crispr Therapeutics maintains a strong cash position of approximately $1.7 billion. The company is focused on advancing its pipeline with upcoming milestones, such as presenting complete Phase 1 data for CTX310. However, a recent price target adjustment by BofA reflects cautious optimism, likely influenced by the company’s financial performance and strategic developments in its gene-editing and immunotherapy programs.
Spark’s Take on CRSP Stock
According to Spark, TipRanks’ AI Analyst, CRSP is a Neutral.
Crispr Therapeutics AG’s stock score reflects the significant financial challenges it faces, particularly regarding revenue and profitability. However, positive corporate events and some technical momentum provide a more balanced outlook, although high volatility and valuation concerns remain.
To see Spark’s full report on CRSP stock, click here.
More about Crispr Therapeutics AG
YTD Price Performance: 35.07%
Average Trading Volume: 3,158,871
Technical Sentiment Signal: Buy
Current Market Cap: $5.12B